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Pancreatic ductal adenocarcinoma (PDAC) ranks as the fourth commonest cause of cancer
death while its incidence is increasing worldwide. For all stages, survival at 5 years is<5%.
The lethal nature of pancreatic cancer is attributed to its high metastatic potential to the
lymphatic system and distant organs. Lack of effective therapeutic options contributes to
the high mortality rates of PDAC. Recent evidence suggests that epithelial-mesenchymal
transition (EMT) plays an important role to the disease progression and development of
drug resistance in PDAC. Tumor budding is thought to reflect the process of EMT which
allows neoplastic epithelial cells to acquire a mesenchymal phenotype thus increasing their
capacity for migration and invasion and help them become resistant to apoptotic signals.
In a recent study by our own group the presence and prognostic significance of tumor
budding in PDAC were investigated and an association between high-grade budding and
aggressive clinicopathological features of the tumors as well as worse outcome of the
patients was found.The identification of EMT phenotypic targets may help identifying new
molecules so that future therapeutic strategies directed specifically against them could
potentially have an impact on drug resistance and invasiveness and hence improve the
prognosis of PDAC patients. The aim of this short review is to present an insight on the
morphological and molecular aspects of EMT and on the factors that are involved in the
induction of EMT in PDAC.
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PANCREATIC CANCER
Pancreatic ductal adenocarcinoma (PDAC) is a common can-
cer with dismal prognosis (1) that escapes early detection and
resists treatment (2). Most patients have advanced stage dis-
ease at presentation with a median survival of less than 1 year
(1, 3). Surgical resection is the only potentially curative treat-
ment of PDAC (3). Classical histomorphological features like
tumor size, blood vessel, or lymphatic invasion, and presence
of lymph node metastases constitute essential prognostic deter-
minants in pancreatic cancer and are invariably included in the
pathology reports, with tumor stage being the most important
of all (3). The lethal nature of PDAC has been attributed to
the propensity of PDAC cells to rapidly disseminate to the lym-
phatic system and distant organs (4). However, even patients
with completely resected, node-negative PDACs eventually die of
their disease. Within this context and considering the fact that
the management of PDAC remains suboptimal and that adjuvant
therapy has resulted to limited progress, the identification of addi-
tional reliable and reproducible prognostic markers that would
enable better patient stratification and eventually provide a guide
toward a more successful and individualized therapy, is mandatory
(1, 5).
EPITHELIAL-MESENCHYMAL TRANSITION
Epithelial-mesenchymal transition is a biologic process that allows
epithelial cells to undergo the biochemical changes that enable
them to acquire a mesenchymal phenotype, including enhanced
migratory capacity, invasiveness, elevated resistance to apoptosis,
and increased production of extracellular matrix (ECM) compo-
nents (6, 7). EMT is characterized by loss of cell adhesion, down
regulation of E-cadherin expression, acquisition of mesenchy-
mal markers (including N-cadherin, Vimentin, and Fibronectin),
and increased cell motility (6). Both EMT and mesenchymal-
epithelial transition (MET), the reversion of EMT, are essential for
developmental and repair processes like implantation, embryo for-
mation, and organ development as well as wound healing, tissue
regeneration, and organ fibrosis (8). However, EMT also occurs
in neoplastic cells that have undergone genetic and epigenetic
changes. These changes affect both oncogenes and tumor sup-
pressor genes that enable cancer cells to invade and metastasize.
Moreover, some neoplastic cells may go through EMT retaining
many of their epithelial properties while other cells are becoming
fully mesenchymal (9).
Many molecular processes are involved in the initiation of EMT
including activation of transcription factors, expression of specific
cell-surface proteins, reorganization and expression of cytoskeletal
proteins, production of ECM-degrading enzymes, and changes in
the expression of specific microRNAs (miRNAS). The above fac-
tors can also be used as biomarkers to detect cells in EMT state (10).
EMT has been linked to cellular self-renewal programs of cancer
stem cells and apoptosis-anoikis resistance, which are features of
therapeutic resistance (11).
www.frontiersin.org September 2013 | Volume 3 | Article 221 | 1
Karamitopoulou EMT in pancreatic cancer
The zinc finger transcription factors Snail, Slug, Zeb1, and
Twist repress genes responsible for the epithelial phenotype and
represent important regulators of EMT (6, 7, 12). In PDAC Snail
expression has been reported to be seen in nearly 80% of the
cases and Slug expression in 50% (13). Snail expression was
inversely correlated with E-cadherin expression and decreased
E-cadherin expression was associated with higher tumor grade.
Similarly, poorly differentiated pancreatic cancer cell lines showed
higher levels of Snail and lower levels of E-cadherin compared
with moderately differentiated cell lines (13) while silencing of
Zeb1 leaded to up-regulation of E-cadherin and restoration of an
epithelial phenotype (14). Zeb1 expression in PDAC also corre-
lated with advanced tumor grade and worse outcomes (14–16)
and was shown to be primarily responsible for the acquisition of
an EMT phenotype, along with increased migration and inva-
sion in response to NF-κB signaling in pancreatic cancer cells
(16).
EMT AND TUMOR BUDDING
Tumor budding reflects a type of diffusely infiltrative growth con-
sisting of detached tumor cells or small cell clusters of up to five
cells at the invasive front of gastrointestinal carcinomas (17–22).
Tumor buds represent a non-proliferating, non-apoptotic, highly
aggressive subpopulation of tumor cells that display migratory
and invasive capacities (23). The aim of tumor buds seems to be
the invasion of the peritumoral connective tissue, the avoidance of
the host’s defense and finally the infiltration of the lymphatic and
blood vessels with the consequence of local and distant metastasis.
The EMT process by allowing a polarized cell to assume a more
mesenchymal phenotype with increased migratory capacity, inva-
siveness, and resistance to apoptosis seems to play a major role in
the development of tumor buds. In fact, tumor buds are thought
to result from the process of EMT. Thus, although formally tumor
budding cannot be equated with EMT, several similarities between
the two processes, including activation in WNT signaling, can
be shown (24). The detachment of tumor buds from the main
tumor body is accomplished by loss of membranous expression
of the adhesion molecule E-cadherin. Activation of WNT sig-
naling is further suggested by nuclear expression of b-catenin in
tumor-budding cells, as well as increase of laminin 5 gamma 2 and
activation of Slug and Zeb1 (24, 25).
The presence of high-grade tumor budding has been consis-
tently associated with negative clinicopathologic parameters in
gastrointestinal tumors (26–30). In a previous study from our
group we could show that tumor budding occurs frequently in
pancreatic cancer and is a strong, independent, and reproducible,
highly unfavorable prognostic factor that may be used as a para-
meter of tumor aggressiveness and as an indicator of unfavorable
outcome, even within this group of patients with generally poor
prognosis. Moreover, tumor budding was proven to have a more
powerful prognostic ability than other more classic prognostic fac-
tors including TNM stage, thus adding relevant and independent
prognostic information (31).
EMT AND miRNAs
MicroRNAS are small non-coding RNAs of 18–25 nucleotides,
excised from 60 to 110 nucleotide RNA precursor structures
(32). MiRNAs are involved in crucial biological processes,
including development, differentiation, apoptosis, and pro-
liferation, through imperfect pairing with target messenger
RNAs of protein-coding genes and the transcriptional or post-
transcriptional regulation of their expression (33, 34).
Recent studies illustrate the role of miRNAs on the regula-
tion of gene expression and proteins in metastasis. For exam-
ple, it has been shown that miR-10b, which is up-regulated
by EMT transcription factor Twist, is associated with increased
invasiveness and metastatic potential (35, 36). Furthermore, it
was shown that the miR-200 family (miR-200a, miR-200b, miR-
200c, miR-141, and miR-429) and miR-205 play critical roles
in regulating EMT by directly targeting the mRNAs encoding
E-cadherin repressors Zeb1 and Zeb2 (37). Moreover, recent
studies showed that members of the miR-200 family by induc-
ing EMT can regulate the sensitivity to epidermal growth fac-
tor receptor (EGFR) in bladder cancer cells and to gemcitabine
in pancreatic cancer cells (38). Conversely, Zeb1 represses the
transcription of miR-200 genes by directly binding to their
promoter region, thereby forming a double-negative feedback
loop (39). On the other hand, miR-200 family can also pro-
mote the conversion of mesenchymal cells to epithelial-like cells
(MET) suggesting that these miRNAs may also favor metastatic
outgrowth.
Recent studies aiming at the evaluation of miRNAs in pan-
creatic cancer have shown that specific miRNAs are dysregulated
in PDAC while the higher expression of some miRNA species
was able to distinguish between benign and malignant pancre-
atic tissue (40). For example, miR-21 was shown to be over-
expressed in 79% of pancreatic cancers as opposed to 27% of
chronic pancreatitis (41). In resected PDAC specimens high lev-
els of miR-200c expression strongly correlated with E-cadherin
levels and were associated with significantly better survival rates
compared with patients whose tumors had low levels of miR-200c
expression (42).
CHEMORESISTANCE AND EMT
Cells undergoing EMT become invasive and develop resistance
to chemotherapeutic agents. Moreover, EMT can be induced
by chemotherapeutic agents, and stress conditions such as
exposure to radiation or hypoxia (43, 44). Up-regulation of
Twist has been shown to be associated with resistance to
paclitaxel in nasopharyngeal, bladder, ovarian, and prostate
cancers (45). In colorectal cancer cell lines, chronic expo-
sure to oxaliplatin leaded to the development of the ability
to migrate and invade with phenotypic changes resembling
EMT (spindle-cell shape, loss of polarity, intercellular separa-
tion, and pseudopodia formation) by the oxaliplatin-resistant
cells (46).
Pancreatic cancer remains today an extremely lethal disease
largely because of its resistance to existing treatments (47). EMT
has been shown to contribute significantly to chemoresistance in
several cancers, including pancreatic cancer (30, 48, 49). Induction
of gemcitabine resistance in previously sensitive cell lines resulted
in development of an EMT phenotype and was associated with
an increased migratory and invasive ability compared to gemc-
itabine sensitive cells (49). Moreover, gene expression profiling of
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FIGURE 1 | Schematic representation of the EMT process in pancreatic cancer depicting the hypothetical link to tumor budding.
chemoresistant cells showed a strong association between expres-
sion of the EMT transcription factors Zeb1, Snail, and Twist and
decreased expression of E-cadherin (39, 50). Silencing of Zeb1
with siRNA resulted to MET (51) and restored chemosensitivity
(14). Interestingly, maintenance of chemoresistance in cell lines
that have undergone EMT is dependent on Notch and NF-κB
signaling (30). Inhibition of Notch-2 down regulates Zeb1, Snail,
and Slug expression, attenuates NF-κB signaling, and reduces
the migratory and invasive capacity of the gemcitabine resistant
cells (30).
Epithelial-mesenchymal transition can also confer resistance
to targeted agents. For example, lung cancer cell lines that
have undergone EMT, became resistant to the growth inhibitory
effects of EGFR kinase inhibition (erlotinib) in vitro and in
xenografts (47) as well as other EGFR inhibitors such as
gefitinib and cetuximab (48) Thus, EMT can lead to resis-
tance to multiple agents and result to rapid progression
of the tumor. Clarifying the correlation between EMT and
drug resistance may help clinicians select an optimal treat-
ment.
CONCLUSION
Pancreatic cancer remains an extremely lethal disease partly
because of the poor response to existing treatments. Accumulat-
ing evidence suggests that EMT plays an important role in PDAC
progression, is associated with stem cell features of the PDAC cells
and seems to significantly contribute to the chemoresistance of
pancreatic cancer. Moreover, is associated with more aggressive
tumor characteristics and with poor patient survival. Because of
its role in therapy response and tumor progression, targeting EMT
could potentially reduce drug resistance and have a great impact
in the survival of PDAC patients.
Tumor budding thought to be the result of the EMT process is
commonly observed in PDAC and high-grade tumor budding has
been proven to have an independent adverse prognostic impact
in the survival of PDAC patients. Figure 1 depicts tumor bud-
ding as a possible transition between a fully epithelial and a fully
mesenchymal phenotype of the tumor cells in PDAC. Moreover,
cancer cells in tumor buds have been shown to have EMT and
cancer stem cell characteristics. The further characterization of
the budding cells at a protein and gene level in order to iden-
tify a “molecular budding-promoting profile” will lead to a better
understanding of the tumor-stroma interaction at the area of the
invasive front and help to further elucidate the similarities between
budding cells, EMT process and cancer stem cells in pancreatic
cancer.
Investigating these issues will allow us to gain further insight
into pancreatic carcinogenesis, and provide us with a platform on
which to build future studies leading to the identification of new
therapeutic interventions.
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